Vident Investment Advisory LLC Takes Position in Iqvia Holdings Inc (IQV)

Vident Investment Advisory LLC bought a new stake in Iqvia Holdings Inc (NYSE:IQV) in the 4th quarter, HoldingsChannel.com reports. The fund bought 5,755 shares of the medical research company’s stock, valued at approximately $563,000.

A number of other institutional investors also recently bought and sold shares of the stock. BlackRock Inc. acquired a new stake in Iqvia in the 4th quarter valued at approximately $942,532,000. Longview Partners Guernsey LTD acquired a new stake in Iqvia in the 4th quarter valued at approximately $927,548,000. Jackson Square Partners LLC acquired a new stake in Iqvia in the 4th quarter valued at approximately $464,053,000. Farallon Capital Management LLC acquired a new stake in Iqvia in the 4th quarter valued at approximately $290,072,000. Finally, Alliancebernstein L.P. acquired a new position in shares of Iqvia in the fourth quarter worth $253,128,000. Hedge funds and other institutional investors own 92.33% of the company’s stock.

Several research firms have commented on IQV. Zacks Investment Research downgraded shares of Iqvia from a “buy” rating to a “hold” rating in a research note on Friday, January 19th. JPMorgan Chase & Co. boosted their price target on shares of Iqvia from $115.00 to $120.00 and gave the stock an “overweight” rating in a research note on Thursday, February 15th. ValuEngine upgraded shares of Iqvia from a “hold” rating to a “buy” rating in a research note on Tuesday, February 20th. Royal Bank of Canada set a $118.00 price target on shares of Iqvia and gave the stock a “buy” rating in a research note on Thursday, February 15th. Finally, TheStreet upgraded shares of Iqvia from a “c+” rating to a “b” rating in a research note on Wednesday, December 13th. Seven investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. Iqvia has a consensus rating of “Buy” and a consensus target price of $110.02.

In other news, insider James H. Erlinger III sold 10,000 shares of Iqvia stock in a transaction on Monday, February 26th. The shares were sold at an average price of $100.00, for a total transaction of $1,000,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Michael J. Evanisko sold 816 shares of Iqvia stock in a transaction on Monday, March 5th. The stock was sold at an average price of $100.00, for a total transaction of $81,600.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 21,712 shares of company stock valued at $2,176,034. Corporate insiders own 6.00% of the company’s stock.

Shares of Iqvia stock opened at $99.72 on Friday. The stock has a market cap of $20,768.69, a price-to-earnings ratio of 16.48, a PEG ratio of 1.44 and a beta of 0.64. Iqvia Holdings Inc has a 1 year low of $77.16 and a 1 year high of $110.67. The company has a debt-to-equity ratio of 1.21, a quick ratio of 1.19 and a current ratio of 1.19.

Iqvia (NYSE:IQV) last released its quarterly earnings data on Wednesday, February 14th. The medical research company reported $1.32 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.34 by ($0.02). The firm had revenue of $2.16 billion for the quarter, compared to analysts’ expectations of $2.14 billion. Iqvia had a return on equity of 13.03% and a net margin of 13.44%. Iqvia’s revenue for the quarter was up 10.7% on a year-over-year basis. During the same period last year, the firm posted $1.09 earnings per share. research analysts anticipate that Iqvia Holdings Inc will post 5.02 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Vident Investment Advisory LLC Takes Position in Iqvia Holdings Inc (IQV)” was originally posted by Ticker Report and is owned by of Ticker Report. If you are viewing this story on another site, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this story can be read at https://www.tickerreport.com/banking-finance/3299819/vident-investment-advisory-llc-takes-position-in-iqvia-holdings-inc-iqv.html.

Iqvia Company Profile

IQVIA Holdings Inc, formerly Quintiles IMS Holdings, Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).

Institutional Ownership by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Stock Analysts’ Downgrades for April, 27th
Stock Analysts’ Downgrades for April, 27th
Ryder  PT Lowered to $76.00
Ryder PT Lowered to $76.00
The Hackett Group  Stock Rating Lowered by Zacks Investment Research
The Hackett Group Stock Rating Lowered by Zacks Investment Research
IMI  Stock Rating Lowered by Zacks Investment Research
IMI Stock Rating Lowered by Zacks Investment Research
Zacks Investment Research Upgrades Healthcare Trust Of America  to Hold
Zacks Investment Research Upgrades Healthcare Trust Of America to Hold
Croda International  Rating Reiterated by Liberum Capital
Croda International Rating Reiterated by Liberum Capital


© 2006-2018 Ticker Report. Google+.